A phase II study of imatinib mesylate (IM) in patients (pts) with unresectable hepatocellular carcinoma (HCC). 41st Annual Meeting of the American-Society-of-Clinical-Oncology LIN, A. Y., Fisher, G., So, S., Tang, C., Levitt, L. AMER SOC CLINICAL ONCOLOGY. 2005: 363S–363S

View details for Web of Science ID 000230326602273